* Aerovate Therapeutics Inc AVTE.OQ reported a quarterly
adjusted loss of 83 cents per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of -67 cents. The mean expectation of six analysts
for the quarter was for a loss of 76 cents per share. Wall
Street expected results to range from -81 cents to -73 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Aerovate Therapeutics Inc's reported EPS for the quarter
was a
loss of 83 cents.
* The company reported a quarterly loss of $23.19 million.
* Aerovate Therapeutics Inc shares had fallen by 32.9% this
quarter and lost 12.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 12.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Aerovate
Therapeutics Inc is $45.50
This summary was machine generated from LSEG data May 13 at
10:13 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.76 -0.83 Missed
Dec. 31 2023 -0.71 -0.74 Missed
Sep. 30 2023 -0.69 -0.71 Missed
Jun. 30 2023 -0.70 -0.76 Missed